Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Japan Sees Showdown of 3 HIF-PH Inhibitors as 2 New Drugs Enter Market
The curtain has risen on a showdown of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in Japan as two new drugs from GlaxoSmithKline and Mitsubishi Tanabe Pharma have now been pitted against Astellas Pharma’s first-in-class drug Evrenzo (roxadustat) in the space.…
To read the full story
Related Article
- HIF-PH Drugs’ Sluggish Q1 Sales Signal Tepid Uptake as Side Effect Concerns Weigh
August 10, 2021
- 5-Camp Battle Heating Up in HIF-PH Market; Evrenzo, Duvroq Neck-and-Neck for Top Spot
May 19, 2021
- Mitsubishi Tanabe’s HIF-PH Inhibitor Hit by Shortage Days after Launch on Better-than-Expected Demand
September 2, 2020
BUSINESS
- Astellas Sees Sales Decline through FY2029 on Xtandi LOE, Maps 200 Billion Yen Cuts in 5 Years
May 27, 2026
- ASKA Set to Seek Shareholder OK for Faster Poison Pill Activation
May 27, 2026
- Eylea Biosimilar Shipment Restrictions to Be Lifted on June 5
May 27, 2026
- Bayer’s Low-Dose MRI Contrast Agent Ambelvist Debuts in Japan
May 27, 2026
- Eisai Eyes 1 Trillion yen in FY2028 Sales under 3-Year Plan
May 26, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…